|
|
News Breaks | | | | November 11, 2012 | | 19:56 EDT |  | HZNP | Horizon presents data showing effectiveness of RAYOS
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D. | |
|
News For HZNP From The Last 14 Days Check below for free stories on HZNP the last two weeks. |
|
|
| May 10, 2013 | | 06:34 EDT |  | HZNP | Horizon Pharma reports Q1 adjusted EPS (30c), consensus (35c)
 Subscribe for More Information | |
|
|
|
|
|
|
